fda tirzepatide approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Day 4: Zepbound (Tirzepatide –

Weight loss during this period accelerates

This targeted strategy can lead to faster, more significant improvements in cholesterol and cardiovascular markers

For the broader landscape, see our where to buy tirzepatide and how to get semaglutide guides

Quick Takeaways AOD 9604 directly targets fat cell metabolism without affecting appetite or growth hormone pathways Tirzepatide works primarily through appetite suppression and glucose control as a dual GLP-1/GIP agonist Tirzepatide has robust human clinical trial data showing over 20% body weight reduction

A Type I user will never achieve the depth of tan that a Type III user reaches, even with extended dosing